Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:AVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that it has submitted the three clinical protocols for TOTUM•854, indicated in the reduction of blood pressure, to the competent authorities and presents its comprehensive clinical development plan, as announced at the annual meeting of the European Society of Hypertension and of the International Society of Hypertension in April 2021 (Press release dated April 12, 2021).
TOTUM•854 is the second plant-based active substance from the Valbiotis product portfolio to enter Phase II/III clinical trials and will address an unmet medical demand for non-drug prevention of arterial hypertension.
The TOTUM•854 clinical development program includes three clinical studies, whose results will be required in Europe and the United States for health claim applications in the reduction of blood pressure, which is a risk factor for cardiovascular disease. The clinical protocols for the three studies have been filed with the competent authorities.
The INSIGHT international, multicenter, randomized, placebo-controlled Phase II/III clinical study will be conducted in a population of 400 volunteers with mild to moderate blood pressure elevation (systolic blood pressure between 130 mmHg and 159 mmHg and diastolic pressure <100 mmHg). It will include two groups: a TOTUM•854 group with a dose of 3.7 g/day and a placebo group. Its main objective will be to reduce systolic blood pressure in the TOTUM•854 group after 3 months of supplementation versus the placebo group. 24-hour ambulatory blood pressure measurements will also be taken as a secondary study endpoint. The end of recruitment is expected at the first semester of 2023.
A second INSIGHT 2 international, multicenter, randomized, placebo-controlled study will be conducted on 400 additional subjects with the same inclusion criteria. It will include two groups: a TOTUM•854 group with a dose of 2.6 g/day and a placebo group. Its main objective will be to reduce systolic blood pressure in the TOTUM•854 group after 3 months of supplementation versus the placebo group. It will thus assess the effect of a reduced dose of TOTUM•854 (2.6 g/day) on blood pressure. The end of recruitment is expected at the first semester of 2023.
The clinical study of the bioavailability and mode of action of TOTUM•854, to characterize its metabolites and identify their effects on human cell lines, will be conducted in France on 10 volunteers. The results are expected at the end of 2022.
Murielle CAZAUBIEL, Member of the Board of Directors and Director of Medical, Regulatory and Industrial Affairs at Valbiotis, said: “TOTUM•854’s clinical development plan is very ambitious, but meets the health challenges of preventing arterial hypertension, which the World Health Organization considers to be the world’s most prevalent chronic disease. It is a very important risk factor for cardiovascular disease. TOTUM•854 could quickly become an extremely interesting non-drug alternative for people at risk, whether or not they are already taking treatment. This innovative active substance, which contains six plant extracts, is designed to act on blood pressure regulation mechanisms. It would ultimately be produced in various dry forms, including as capsules.”
Sébastien BESSY, Member of the Board of Directors and Chief Operating Marketing and Business Officer at Valbiotis, comments: “TOTUM•854 will open the door to a major market worth over €1.15 billion1 in the United States and in the five main European countries (Germany, Spain, France, Italy and the United Kingdom), where no fewer than 124 million people suffer from mild to moderate arterial hypertension. This clinical development plan will leverage the potential of TOTUM•854 in preventing arterial hypertension, with the aim of bringing it to market as soon as the studies ends. In addition, we have registered TOTUM•854 in over 60 countries, including our key territories such as the United States, Europe, Mexico, China, Japan and already obtained in some of these territories.”
Valbiotis presented its preclinical data on the active substance TOTUM•854 at the annual meeting of the European Society of Hypertension and of the International Society of Hypertension in April 2021. The in vivo results obtained from two predictive models of hypertension in humans showed that TOTUM•854 effectively prevented arterial hypertension. This proof-of-concept was obtained in partnership with the Cardiovascular Pharm-Ecology Lab (LaPEC) of the University of Avignon and at the Valbiotis R&D platform. The research presented at the meeting was conducted on a model of L-NAME-induced hypertension (an NO synthase inhibitor). In this classic model of hypertension, predictive of human physiology, TOTUM•854 prevented the onset of arterial hypertension compared with the control group. Additional data, obtained from a polygenic SHR (spontaneously hypertensive rat) model of hypertension, also showed a positive effect of TOTUM•854 that delays the development of hypertension.
A significant acute effect was also observed following a single dose of TOTUM•854 on the same SHR model.
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.
1Source: AEC Partners pre-AHT preliminary market estimate 2020 data
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Corporate communication / Valbiotis
Carole Rocher / Marc Delaunay
+33 5 46 28 62 58
Financial communication / Actifin
+33 1 56 88 11 14
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vending Machines International Secures SGD 135 Million Capital Commitment From Global Emerging Markets (GEM) as Company Seeks to Go Public26.1.2022 05:02:00 CET | Press release
Vending Machines International (VMI), today announced a SGD 135 Million capital commitment from GEM Global Yield LLC SCS ("GGY"), the Luxembourg-based private alternative investment vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125006251/en/ (Photo: Business Wire) Under the agreement, GGY will provide VMI with a Share Subscription Facility of up to SGD 135 million for a 36-month period following a public listing of VMI’s common stock. VMI will control the timing and maximum amount of drawdowns under this facility and has no minimum drawdown obligation. “VMI is very pleased to be selected by the GEM Group to receive this investment. It is a credit to the GEM management that they very quickly grasped that the world is moving to remove single use plastics from the supply chain. VMI is extremely well placed to take advantage of this transition. With GEM’s funds to strengthen the VMI balance sheet VMI will be able to
Private Messaging App Launches on Quantum Resistant, Decentralized xx network25.1.2022 16:30:00 CET | Press release
The world’s first quantum-resistant messaging app, xx messenger, launched on the xx network today. xx messenger allows users to communicate in real time through hundreds of decentralized nodes operating worldwide. The app is available for download on IOS and Android, features group chat as well as photo and audio sharing, and designed for easy use and switching to from legacy messaging apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005773/en/ David Chaum (Photo: Business Wire) Unlike existing messaging apps, xx messenger uses quantum-resistant cryptography to protect message content from decoding and cMix software to obfuscate or shred metadata—information about who sends, when they send, where they send from, and who receives. Randomly selected teams of xx nodes encrypt anonymity sets of 1,000 messages, which are then repeatedly shuffled and have also been encrypted using quantum-resistant cryptography. Informat
MDSLink Makes MaGiC™25.1.2022 16:00:00 CET | Press release
In response to the fiber buildout worldwide, and the continuous demand for reliable bandwidth, MDSLink, Inc. is now offering MaGiC™, a very high-performance, networking module that uses the existing coax. MaGiC is a cost-effective, easy-to-install module that extends the fiber footprint found in MDUs, single-family homes, hotels/resorts and offices or any building with existing coax. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005534/en/ MaGiC Small Form Factor Pluggable (Photo: Business Wire) MaGiC-SFP 2.5™ (Multi-Gigabit Coax Small Form-factor Pluggable) provides up to 2.5 Gbps—symmetrical—actual data rates when plugged into an Ethernet network (SFP/SFP+ port). Applications: - Last 100-meter distribution using existing, in-building coax. - Wireless AP backhaul in-premise. Supplements in-home Wi-Fi® mesh networks using fail safe, wireline backhaul between devices. Using WAPs with SFP-ports, operators can backhaul t
Kroll Unifies Brand to Reflect Strategic Growth and Vision25.1.2022 16:00:00 CET | Press release
Kroll, the leading provider of data, technology and insights related to risk, governance and growth, announces today the completion of its transition to a unified brand. Through its combined capabilities, Kroll is uniquely positioned to help clients stay ahead of complex business demands and opportunities across dynamic regulatory, economic and risk environments. “Our brand unification is a necessary evolution to deliver superior client service and meet and anticipate our clients’ increasingly complex and interconnected needs,” said Jacob Silverman, Chief Executive Officer of Kroll, “This marks the beginning of a new chapter for Kroll that reflects our market leadership across borders and disciplines, and embraces our proprietary data, technology and insights to create value and impact for our clients and communities.” Last year, the Company announced plans to unify its business following significant organic growth and strategic acquisitions. Kroll’s full suite of solutions now span se
Dr. Philip Krause to Provide Strategic Advice to Adjuvance25.1.2022 15:35:00 CET | Press release
Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced that Philip Krause, MD, will take on a strategic consulting role with the organization as it advances its vaccine development portfolio. Dr. Krause recently served as the Deputy Director, Office of Vaccines Research and Review of the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research. “The deep scientific, regulatory and vaccine development experience that Phil brings to Adjuvance will be instrumental in efficiently developing our shingles vaccine candidate and our pipeline anchored on the next-generation saponin adjuvant TQL-1055,” noted Dr. Tyler Martin, Adjuvance CEO, President and Chairman. “I am thrilled to enhance the company’s expertise with such a well-respected scientist.” Dr. Krause previously had a 30-year career in the FDA where he made majo
Andersen Global Adds Member Firms in Croatia25.1.2022 15:30:00 CET | Press release
Andersen Global continues to cultivate a strong European presence as Croatian tax and advisory firm Andersen BD d.o.o. (formerly BD Savjetovanje d.o.o.) becomes the organization’s newest member firm to adopt the Andersen brand. Andersen Global also welcomes member firm KALLAY & PARTNERS, a Zagreb-based law firm and collaborating firm since 2019. Together, the member firms will provide complementary tax and legal solutions, demonstrating the unified and seamless approach of the global organization. “As tax and legal legislation globally becomes more complex, we aim to continue providing best-in-class service and help our clients navigate the various aspects of their business operations,” said Branka Topolovec new Managing Partner of Andersen in Croatia. “The adoption of the Andersen brand is a milestone for our firm’s growth and development and gives us a competitive advantage in the market by allowing us to provide our clients with a full suite of capabilities in Croatia as well as glo
UVD Robots Joins Ecolab’s Global Infection Prevention Offerings to Fight Hospital Acquired Infections25.1.2022 15:02:00 CET | Press release
As new coronavirus variants spread, the growth in demand for infection prevention solutions using UV-C light is projected to reach $18.94 billion by 2030, witnessing an annual growth rate of 59.7% from 2021 to 2030. Further fueling the demand is the rise in hospital acquired infections (HAIs) globally causing more fatalities due to the increase in antibiotic resistance from even simple infections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005148/en/ Disinfecting hospitals with UV-C lights is not a new concept, however, existing solutions including UV ceiling lights, stationary cleaning robots, and air purifiers may not reach shadowed or remote areas as well as the mobile platform offered by the autonomous UVD Robots. (Photo: Business Wire) Autonomous UV-C disinfection robots have emerged as a solution to supplement standard cleaning and disinfection practices to address HAIs and heightened hygiene requirements due
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom